Avalyn Pharma Q2 2026: $413.5M Cash Funds Pipeline into 2029, Key Clinical Data Readouts in 2027
AVLN sits 45% above its 52-week low of $24.15.
Summary
Avalyn Pharma reported Q2 2026 results with $413.5M in cash and securities, funding operations into 2029. Lead programs AP01 and AP02 remain on track for pivotal data in 2027.
Key Events · Earnings and Guidance · AVLN
-
Cash Runway Extended into 2029
Cash, equivalents, and marketable securities totaled $413.5 million as of June 30, 2026, following the $316.6 million IPO. Management expects this to fund operations into 2029, beyond key data readouts.
-
Lead Programs on Track for 2027 Data
AP01 (inhaled pirfenidone) Phase 2b MIST trial topline data expected in H2 2027; AP02 (inhaled nintedanib) Phase 2 AURA trial topline data expected in late 2027. AP03 Phase 1 initiation planned by end of 2026.
-
IPO and Reverse Split Reshape Capital Structure
A 1-for-19.2417 reverse stock split became effective April 22, 2026. The IPO closed May 1, 2026, with 19.2 million shares sold at $18.00, raising $316.6 million. All preferred stock converted to common.
-
New Term Loan Adds $15 Million
In February 2026, the company drew $15 million under a $30 million term loan facility with Banc of California, with an additional $15 million available through December 2027. Interest rate is the greater of prime or 5%.
Analysis · AVLN · Life Sciences
With a post-IPO cash position of $413.5 million, Avalyn Pharma's Q2 2026 report extends its runway into 2029 — well past the anticipated topline data readouts for lead programs AP01 (H2 2027) and AP02 (late 2027). The company is advancing three clinical-stage inhaled antifibrotic candidates for pulmonary fibrosis, a market with significant unmet need. Operating expenses are rising as trials progress, but the balance sheet provides ample cushion. The reverse stock split and IPO have transformed the capital structure, eliminating preferred stock and establishing a clean public-company equity base. The report also discloses a new $15 million term loan, adding modest leverage. For a clinical-stage biotech, the combination of extended runway and near-term catalysts makes this a notable update.
At the time of this filing, AVLN was trading at $35.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $24.15 to $35.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.